Q-omics provides the consensus-scored AMTN profile across patient tissues and cancer cell-line models. AMTN expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, AMTN is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, AMTN RNA expression shows 10,738 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, HNSC, and TGCT as cancer lineages where AMTN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AMTN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AMTN survival associations across molecular data types. AMTN RNA expression shows survival associations in the most cancer types (15), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AMTN RNA expression–survival associations across cancer types. High AMTN expression shows unfavorable associations in LIHC, KIRC, MESO, BRCA and SCLC, but favorable associations in HNSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for AMTN RNA expression.
This table summarizes AMTN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for AMTN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AMTN shows lower tumor expression in KIRC and higher tumor expression in HNSC, LUSC, BLCA, THCA and UCEC. The HNSC box plot shows higher AMTN RNA expression in tumor versus normal tissue (log2 FC = +3.483, t-test p < 0.001).
This table shows molecular features associated with AMTN in patient tissues and cancer cell lines. In patient samples, AMTN shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, AMTN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SKIN.
